[1]李治璇,桂腾娟,孙紫娟,等.半乳糖凝集素-3及糖基化终末产物对糖尿病肾病的影响[J].医学信息,2023,36(03):173-176.[doi:10.3969/j.issn.1006-1959.2023.03.038]
 LI Zhi-xuan,GUI Teng-juan,SUN Zi-juan,et al.The Effects of Galectin-3 and Glycation End Products on Diabetic Kidney Disease[J].Journal of Medical Information,2023,36(03):173-176.[doi:10.3969/j.issn.1006-1959.2023.03.038]
点击复制

半乳糖凝集素-3及糖基化终末产物对糖尿病肾病的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年03期
页码:
173-176
栏目:
综述
出版日期:
2023-02-01

文章信息/Info

Title:
The Effects of Galectin-3 and Glycation End Products on Diabetic Kidney Disease
文章编号:
1006-1959(2023)03-0173-04
作者:
李治璇桂腾娟孙紫娟
(昆明医科大学第一附属医院肾内科,云南 昆明 650032)
Author(s):
LI Zhi-xuanGUI Teng-juanSUN Zi-juanet al.
(Department of Nephrology,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,Yunnan,China)
关键词:
糖尿病肾病半乳糖凝集素-3晚期糖基化终末产物生物学标志物
Keywords:
Diabetic kidney diseaseGalectin-3Advanced glycation end productsBiological markers
分类号:
R587.2
DOI:
10.3969/j.issn.1006-1959.2023.03.038
文献标志码:
A
摘要:
糖尿病肾病(DKD)是糖尿病患者常见的并发症,也是其主要死因之一。然而DKD起病隐匿,因此需要早发现、早治疗。在DKD的发病机制中,晚期糖基化终末产物(AGEs)有重要作用,而半乳糖凝集素-3(Gal-3)作为AGEs的一个受体,其与DKD的关系仍存在争议。故本文对AGEs及Gal-3对DKD的影响机制进行综述,以期为临床治疗提供参考。
Abstract:
Diabetic kedney disease (DKD) is a common complication and one of the main causes of death of diabetic mellitus patients. However, the onset of DKD is insidious, early detection and treatment is necessary for it. Advanced glycation end products (AGEs) play an important role in the pathogenesis of DKD. Galectin-3 (Gal-3), as a receptor of AGEs, its relationship with DKD is still controversial. Therefore, this article reviews AGEs and Gal-3 on DKD in order to provide reference for clinical treatment.

参考文献/References:

[1]中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(3):225-304.[2]Ruiz OM,Rodrigues DR,Lavoz C,et al.Special Issue "Diabetic Nephropathy: Diagnosis,Prevention and Treatment"[J].J Clin Med,2020,9(3):813.[3]Hu R,Quan S,Wang Y,et al.Spectrum of biopsy proven renal diseases in Central China: a10-year retrospective study based on 34,630 cases[J].Sci Rep,2020,10(1):10994.[4]Yang C,Wang H,Zhao X,et al.CKD in China:Evolving Spectrum and Public Health Implications[J].Am J Kidney Dis,2020,76(2):258-264.[5]翟英,李向东,李毅,等.高通量透析对糖尿病肾脏疾病患者糖基化终产物及微炎症的影响[J].临床肾脏病杂志,2018,18(7):409-412.[6]Ho JE,Liu C,Lyass A,et al.Galectin-3,a marker of cardiac fibrosis,predicts incident heart failure in the community[J].J Am Coll Cardiol,2012,60(14):1249-1256.[7]Alicic RZ,Rooney MT,Tuttle KR.Diabetic Kidney Disease:Challenges,Progress,and Possibilities[J].Clin J Am Soc Nephrol,2017,12(12):2032-2045.[8]Heilig CW,Deb DK,Abdul A,et al.GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy[J].Am J Nephrol,2013,38(1):39-49.[9]Samsu N.Diabetic Nephropathy: Challenges in Pathogenesis,Diagnosis,and Treatment[J].Biomed Res Int,2021,2021:1497449.[10]Kim KS,Park SW,Cho YW,et al.Higher Prevalence and Progression Rate of ChronicKidney Disease in Elderly Patients with Type 2 Diabetes Mellitus[J].Diabetes Metab J,2018,42(3):224-232.[11]Thomas MC,Cooper ME,Zimmet P.Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease[J].Nat Rev Nephrol,2016,12(2):73-81.[12]Perrone A,Giovino A,Benny J,et al.Advanced Glycation End Products (AGEs): Biochemistry,Signaling,Analytical Methods,and Epigenetic Effects[J].Oxid Med Cell Longev,2020,2020:3818196.[13]Snelson M,Coughlan MT.Dietary Advanced Glycation End Products: Digestion,Metabolismand Modulation of Gut Microbial Ecology[J].Nutrients,2019,11(2):215.[14]李兰,李建薇.糖尿病肾病患者糖脂代谢状况与肾功能、炎症反应的相关性[J].海南医学院学报,2017,23(10):1341-1343,1347.[15]Kumar PA,Chitra PS,Reddy GB.Advanced glycation end products mediated cellular andmolecular events in the pathology of diabetic nephropathy[J].Biomol Concepts,2016,7(5-6):293-309.[16]Zhang P,Sun Y,Peng R,et al.Long Non-Coding RNA Rpph1 Promotes Inflammation and Proliferation of Mesangial Cells in Diabetic Nephropathy via an Interaction with Gal-3[J].Cell Death Dis,2019,10:526.[17]Johannes L,Jacob R,Leffler H.Galectins at a glance[J].J Cell Sci,2018,131(9):jcs208884.[18]Newlaczyl AU,Yu LG.Galectin-3--a jack-of-all-trades in cancer[J].Cancer Lett,2011,313(2):123-128.[19]Boutin L,Dépret F,Gayat E,et al.Galectin-3 in Kidney Diseases: From an Old Protein to a New Therapeutic Target[J].Int J Mol Sci,2022,23(6):3124.[20]Sciacchitano S,Lavra L,Morgante A,et al.Galectin-3: One Molecule for an Alphabet of Diseases,from A to Z[J].Int J Mol Sci,2018,19(2):379.[21]Ji F,Zhang S,Jiang X,et al.Diagnostic and prognostic value of galectin-3,serum creatinine,and cystatin C in chronic kidney diseases[J].J Clin Lab Anal,2017,31(5):e22074.[22]O’Seaghdha CM,Hwang SJ,Ho JE,et al.Elevated galectin-3 precedes the development of CKD[J].J Am Soc Nephrol,2013,24(9):1470-1477.[23]Iacoviello M,Aspromonte N,Leone M,et al.Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients[J].Res Cardiovasc Med,2015,5(1):e28952.[24]Yilmaz H,Inan O,Darcin T,et al.Serum galectin-3 levels were associated with proteinuria in patients with Familial Mediterranean Fever[J].Clin Exp Nephrol,2015,19(3):436-442.[25]Hodeib H,Hagras MM,Abdelhai D,et al.Galectin-3 as a prognostic biomarker for diabetic nephropathy[J].Diabetes Metab Syndr Obes,2019,12:325-331.[26]Hussain S,Habib A,Hussain MS,et al.Potential biomarkers for early detection of diabetic kidney disease[J].Diabetes Res Clin Pract,2020,161:108082.[27]Tan KCB,Cheung CL,Lee ACH,et al.Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus[J].Diabetologia,2018,61(5):1212-1219.[28]Drechsler C,Delgado G,Wanner C,et al.Galectin-3,Renal Function,and Clinical Outcomes: Results from the LURIC and 4D Studies[J].J Am Soc Nephrol,2015,26(9):2213-2221.[29]Ozkan G,Ulusoy S,Mentese A,et al.Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?[J].Clin Biochem,2015,48(12):768-773.[30]Hogas S,Schiller A,Voroneanu L,et al.Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients[J].Angiology,2016,67(9):854-859.[31]Yücel N,?覶ak?覦r Madenci ?魻,B?觟lük A,et al.Is galectin-3 associated with urinary albumin excretion in type 2 diabetes?[J].Endokrynol Pol,2016,67(6):580-584.[32]Okamura DM,Pasichnyk K,Lopez-Guisa JM,et al.Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis[J].Am J Physiol Renal Physiol,2011,300(1):F245-F253.[33]Luís C,Costa R,Rodrigues I,et al.Xanthohumol and 8-prenylnaringenin reduce type 2 diabetes-associated oxidative stress by downregulating galectin-3[J].Porto Biomed J,2018,4(1):e23.

相似文献/References:

[1]陈淑雯.肾衰宁联合科素亚治疗早期糖尿病肾病的临床观察[J].医学信息,2018,31(05):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
 CHEN Shu-wen.Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu[J].Journal of Medical Information,2018,31(03):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
[2]何丽杰.中西医治疗糖尿病肾病的临床效果分析[J].医学信息,2018,31(10):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
 HE Li-jie.Clinical Effect Analysis of Diabetic Nephropathy Treated by Chinese and Western Medicine[J].Journal of Medical Information,2018,31(03):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
[3]贺 伟,高 峰.24 h尿微量白蛋白、血清胱抑素C水平与血清肌酐、尿素水平在2型糖尿病肾病早期诊断的意义[J].医学信息,2018,31(11):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
 HE Wei,GAO Feng.The Significance of 24 h Urinary Microalbumin,Serum Cystatin C and Serum Creatinine and Urea Levels in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(03):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
[4]黄秋菊.胱抑素C及脂蛋白α在早期糖尿病肾病诊断中的价值研究[J].医学信息,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
 HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Journal of Medical Information,2018,31(03):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[5]陆新虹,温玉洁,胡 欣,等.α-硫辛酸对2型糖尿病肾病患者 血清内脂素的影响研究[J].医学信息,2018,31(14):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
 LU Xin-hong,WEN Yu-jie,HU Xin,et al.Effect of α-lipoic Acid on Serum Visfatin in Patients with Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(03):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
[6]郑小鹏,辛 华.糖尿病肾病研究进展[J].医学信息,2018,31(16):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
 ZHENG Xiao-peng,XIN Hua.Progress in the Study of Diabetic Nephropathy[J].Journal of Medical Information,2018,31(03):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
[7]李志俊,王 利,王 浩.姜黄素改善糖尿病肾病的作用机制研究[J].医学信息,2018,31(24):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
 LI Zhi-jun,WANG Li,WANG Hao.Study on the Mechanism of Curcumin in Improving Diabetic Nephropathy[J].Journal of Medical Information,2018,31(03):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
[8]肖学秀.益气活血汤联合西药治疗早期糖尿病肾病的临床观察[J].医学信息,2019,32(02):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
 XIAO Xue-xiu.Clinical Observation of Yiqi Huoxue Decoction Combined with Western Medicine in Treating Earlyn Diabetic Nephropathy[J].Journal of Medical Information,2019,32(03):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
[9]张国艳,张佳田,隋洪玉.糖尿病肾病大鼠动物模型建立及INF-α干预机制研究[J].医学信息,2019,32(05):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
 ZHANG Guo-yan,ZHANG Jia-tian,SUI Hong-yu.Establishment of Animal Model of Diabetic Nephropathy Rats and Study of INF-α Intervention Mechanism[J].Journal of Medical Information,2019,32(03):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
[10]吴怡琪,卢 文.皮肤AGEs荧光检测对糖尿病肾病的临床意义[J].医学信息,2019,32(06):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]
 WU Yi-qi,LU Wen.Clinical Significance of Skin AGEs Fluorescence Detection in Diabetic Kidney Disease[J].Journal of Medical Information,2019,32(03):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]

更新日期/Last Update: 1900-01-01